Ortivus (ORTI) Q2 2026 earnings summary

Executive summary

• Net sales for April–June 2026 decreased by 2% year-over-year to SEK 19.3 million, while gross margin dropped to 37% from 51% due to increased hardware sales and replacements.

• EBITDA improved to SEK -2.8 million from SEK -4.7 million, and net profit after tax was SEK -3.6 million, up from SEK -6.5 million in the prior year.

• For January–June 2026, net sales rose 8% year-over-year to SEK 40.8 million, with a gross margin of 42% (down from 46%).

• The company continues to invest in its MobiMed platform, expanding SaaS offerings and entering new markets such as Australia.

Financial highlights

• April–June 2026 net sales: SEK 19.3 million (down 2% year-over-year); gross margin: 37% (down from 51%).

• EBITDA: SEK -2.8 million (improved from SEK -4.7 million); net profit after tax: SEK -3.6 million (improved from SEK -6.5 million).

• January–June 2026 net sales: SEK 40.8 million (up 8% year-over-year); gross margin: 42% (down from 46%).

• Cash and cash equivalents at period end: SEK 6.7 million (up from SEK 1.6 million year-over-year).

• Equity ratio improved to 24% from -26% year-over-year.

Outlook and guidance

• Continued investment in MobiMed platform, with new SaaS applications and expansion into Australia and other English-speaking markets.

• Transition to semi-annual financial reporting; next report will be the 2026 year-end report.

• No formal forecasts provided; forward-looking statements subject to risks and uncertainties.